Trial launches, interim results, approvals, safety signals, and what they may mean for patients.
The FDA’s December 19, 2025 decision could make some osteoporosis drug trials smaller and faster. But it does not change who should get screened, how osteoporosis is diagnosed, or what most patients should do today.
A large randomized trial found that semaglutide reduced heart attacks and strokes in adults with overweight or obesity and established cardiovascular disease who did not have diabetes. Here’s what the evidence shows, what the FDA approval means, and what U.S. patients should know about safety, cost, and coverage.
End of content
End of content